SCHEIBLER LUKAS 4
4 · Apellis Pharmaceuticals, Inc. · Filed May 31, 2022
Insider Transaction Report
Form 4
SCHEIBLER LUKAS
See Remarks
Transactions
- Sale
Common Stock
2022-05-27$43.00/sh−10,000$430,000→ 40,358 total - Other
Common Stock
2022-04-21−1,875→ 50,358 total - Other
Stock Option (Right to Buy)
2022-04-21−11,250→ 0 totalExercise: $44.90Exp: 2031-01-27→ Common Stock (11,250 underlying)
Footnotes (4)
- [F1]This represents the cancellation of a PSU awards granted on 01/28/2021 that was originally reported in table I upon grant. The performance metrics were not met.
- [F2]This is a scheduled sale from 10B5-1 trading plan.
- [F3]This represents the cancellation of a performance stock option granted on 01/28/01. The performance metrics were not met.
- [F4]This stock option will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.